L0909

• CAT Number: I030226
• CAS Number: 2085271-43-6
• Molecular Formula: C23H30ClN5
• Molecular Weight: 411.98
• Purity: 98%
• Synonyms: L0909; L-0909; L 0909
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 2-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-4-((2-(dimethylamino)ethyl)(methyl)amino)benzonitrile
• InChI: InChI=1S/C23H30ClN5/c1-26(2)10-11-27(3)23-7-4-19(17-25)20(16-23)18-28-12-14-29(15-13-28)22-8-5-21(24)6-9-22/h4-9,16H,10-15,18H2,1-3H3
• InChIKey: ZMKYHHMOPNGIDE-UHFFFAOYSA-N
• SMILES: N#CC1=CC=C(N(CCN(C)C)C)C=C1CN2CCN(C3=CC=C(Cl)C=C3)CC2

L0909(CAT: I030226) is a potent and orally available Hepatitis C virus (HCV) entry inhibitor with a novel mechanism of action. It effectively blocks HCV replication by targeting the viral entry stage, preventing the virus from infecting host cells. L0909 demonstrates strong antiviral activity with an EC₅₀ of 0.022 μM and a selectivity index (SI) > 600, indicating high potency and low cytotoxicity. Notably, L0909 shows high efficacy against clinically resistant HCV mutants and exhibits a synergistic effect when combined with existing antiviral drugs, making it a promising candidate for single-agent or combination therapy in HCV treatment.